Keybank National Association OH Sells 83,831 Shares of Johnson & Johnson (NYSE:JNJ)

Keybank National Association OH cut its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 6.7% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,174,588 shares of the company’s stock after selling 83,831 shares during the quarter. Johnson & Johnson makes up 0.7% of Keybank National Association OH’s portfolio, making the stock its 27th largest position. Keybank National Association OH’s holdings in Johnson & Johnson were worth $169,869,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in JNJ. Mainstream Capital Management LLC bought a new stake in shares of Johnson & Johnson in the 4th quarter valued at about $63,000. Ring Mountain Capital LLC bought a new stake in shares of Johnson & Johnson in the 4th quarter valued at about $318,000. Exencial Wealth Advisors LLC raised its holdings in shares of Johnson & Johnson by 2.3% in the 4th quarter. Exencial Wealth Advisors LLC now owns 44,573 shares of the company’s stock valued at $6,446,000 after purchasing an additional 1,000 shares during the period. AMJ Financial Wealth Management raised its holdings in shares of Johnson & Johnson by 508.2% in the 4th quarter. AMJ Financial Wealth Management now owns 6,806 shares of the company’s stock valued at $160,000 after purchasing an additional 5,687 shares during the period. Finally, Commerzbank Aktiengesellschaft FI raised its holdings in shares of Johnson & Johnson by 7.8% in the 4th quarter. Commerzbank Aktiengesellschaft FI now owns 1,076,053 shares of the company’s stock valued at $155,619,000 after purchasing an additional 78,141 shares during the period. 69.55% of the stock is owned by institutional investors.

Insider Buying and Selling

In related news, EVP Timothy Schmid sold 403 shares of the stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $156.15, for a total transaction of $62,928.45. Following the sale, the executive vice president now owns 15,098 shares in the company, valued at approximately $2,357,552.70. This trade represents a 2.60 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Mark A. Weinberger purchased 1,000 shares of Johnson & Johnson stock in a transaction that occurred on Thursday, December 12th. The shares were purchased at an average price of $147.22 per share, for a total transaction of $147,220.00. Following the transaction, the director now directly owns 1,000 shares in the company, valued at $147,220. This represents a ∞ increase in their position. The disclosure for this purchase can be found here. 0.16% of the stock is currently owned by company insiders.

Johnson & Johnson Stock Performance

Shares of NYSE:JNJ opened at $165.22 on Thursday. The company’s 50 day moving average price is $152.11 and its two-hundred day moving average price is $156.19. Johnson & Johnson has a 12-month low of $140.68 and a 12-month high of $169.99. The firm has a market cap of $397.79 billion, a PE ratio of 24.85, a PEG ratio of 2.56 and a beta of 0.52. The company has a quick ratio of 0.86, a current ratio of 1.11 and a debt-to-equity ratio of 0.43.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Wednesday, January 22nd. The company reported $2.04 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.99 by $0.05. The business had revenue of $22.52 billion for the quarter, compared to analyst estimates of $22.44 billion. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. The firm’s revenue for the quarter was up 5.3% on a year-over-year basis. During the same quarter last year, the business posted $2.29 EPS. Equities research analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Tuesday, March 4th. Investors of record on Tuesday, February 18th were given a dividend of $1.24 per share. The ex-dividend date of this dividend was Tuesday, February 18th. This represents a $4.96 annualized dividend and a dividend yield of 3.00%. Johnson & Johnson’s dividend payout ratio is 74.59%.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on JNJ shares. Guggenheim upped their target price on shares of Johnson & Johnson from $162.00 to $166.00 and gave the company a “neutral” rating in a report on Monday, February 3rd. Argus raised shares of Johnson & Johnson to a “strong-buy” rating in a report on Friday, January 24th. Bank of America upped their target price on shares of Johnson & Johnson from $159.00 to $171.00 and gave the company a “neutral” rating in a report on Wednesday. Citigroup lowered their price target on shares of Johnson & Johnson from $185.00 to $175.00 and set a “buy” rating on the stock in a report on Wednesday, December 11th. Finally, Wells Fargo & Company lowered their price target on shares of Johnson & Johnson from $166.00 to $152.00 and set an “equal weight” rating on the stock in a report on Thursday, January 23rd. Nine analysts have rated the stock with a hold rating, eight have issued a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat.com, Johnson & Johnson currently has a consensus rating of “Moderate Buy” and a consensus price target of $171.33.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.